Conclusion: Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
Does Lisdexamfetamine help with focus?
Yes, for most people. 87% of 200 people who reported on Lisdexamfetamine for focus say it improved. 8% noticed no change and 5% say it got worse. That is about the typical result for focus (86% across 80 options).
Across all 280 first-hand reports on Lisdexamfetamine (any goal): worked for 40%, worked with downsides for 41%, did not work for 19%. Most reported side effects: anxiety, insomnia, fatigue, irritability.
Ranked #19 of 80 for focus.
People it helped with focus
“I recently got diagnosed with ADHD and it blows my mind that my anxiety has decreased by about 70% since starting Vyvanse.”
“Vyvanse is better than Adderall in every single way... I feel happy, calm and collected.”
Problems people report with Lisdexamfetamine
“within a few months of her starting on Vyvanse, it completely changed who my wife was.”
“I'm at 40mg, it got better with 40mg compared to 30 but it's still pretty noticeable. I tried 60mg but it caused anxiety and emotional issues and I couldn't sleep.”
“I felt anxious, had headaches, lost sleep and appetite, and overall felt like it made my ADHD worse.”
“Both helped but the comedown is was so bad for both for me. I've had depression for several years and both made me feel very depressed coming off them.”
What the research says
Conclusion: Overall, despite a class effect of improving clinical response relative to placebo, there were few differences among the individual ADHD pharmacotherapies, and most studies were at risk of at least one important source of bias. Furthermore, the certainty of the evidence was very low to low for all outcomes, and there was limited reporting of long-term adverse events. As such, the choice between ADHD pharmacotherapies may depend on individual patient considerations, and future studies should assess the long-term effects of individual pharmacotherapies on patient-important outcomes, including qu
Side effects people mention
What else is Lisdexamfetamine used for?
Information only — not medical advice. How we count